- Home
- ACIU vs DCTH Comparison
ACIU vs DCTH Comparison
Compare ACIU & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- DCTH
- Stock Information
- Founded
- ACIU 2003
- DCTH 1988
- Country
- ACIU Switzerland
- DCTH United States
- Employees
- ACIU N/A
- DCTH N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- ACIU Health Care
- DCTH Health Care
- Exchange
- ACIU Nasdaq
- DCTH Nasdaq
- Market Cap
- ACIU 332.4M
- DCTH N/A
- IPO Year
- ACIU 2016
- DCTH N/A
- Fundamental
- Price
- ACIU $3.15
- DCTH $11.87
- Analyst Decision
- ACIU Strong Buy
- DCTH Strong Buy
- Analyst Count
- ACIU 2
- DCTH 4
- Target Price
- ACIU $12.00
- DCTH $21.50
- AVG Volume (30 Days)
- ACIU 151.5K
- DCTH 480.6K
- Earning Date
- ACIU 11-05-2024
- DCTH 11-08-2024
- Dividend Yield
- ACIU N/A
- DCTH N/A
- EPS Growth
- ACIU N/A
- DCTH N/A
- EPS
- ACIU N/A
- DCTH N/A
- Revenue
- ACIU $48,505,404.00
- DCTH $22,644,000.00
- Revenue This Year
- ACIU $85.33
- DCTH $1,605.13
- Revenue Next Year
- ACIU $80.69
- DCTH $111.67
- P/E Ratio
- ACIU N/A
- DCTH N/A
- Revenue Growth
- ACIU 4097200.00
- DCTH 945.91
- 52 Week Low
- ACIU $2.25
- DCTH $2.84
- 52 Week High
- ACIU $5.14
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- ACIU 45.68
- DCTH 61.82
- Support Level
- ACIU $3.10
- DCTH $11.42
- Resistance Level
- ACIU $3.25
- DCTH $12.79
- Average True Range (ATR)
- ACIU 0.14
- DCTH 0.66
- MACD
- ACIU -0.02
- DCTH 0.15
- Stochastic Oscillator
- ACIU 13.16
- DCTH 74.17
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.